The estimated Net Worth of Michael F Demane is at least $59.7 millió dollars as of 12 April 2023. Mr. Demane owns over 80,291 units of Nevro Corp stock worth over $475,795 and over the last 10 years he sold NVRO stock worth over $58,900,367. In addition, he makes $279,955 as Lead Independent Director at Nevro Corp.
Michael has made over 38 trades of the Nevro Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 80,291 units of NVRO stock worth $1,445,238 on 12 April 2023.
The largest trade he's ever made was exercising 139,514 units of Nevro Corp stock on 4 October 2016 worth over $2,435,914. On average, Michael trades about 16,787 units every 45 days since 2014. As of 12 April 2023 he still owns at least 101,018 units of Nevro Corp stock.
You can see the complete history of Mr. Demane stock trades at the bottom of the page.
Michael F. DeMane serves as Lead Independent Director of the Company. Effective January 1, 2017, Mr. DeMane transitioned to non-executive Chairman of the Board. In May 2019, Mr. DeMane became our Lead Director. Mr. DeMane has served on the board of directors of several private companies since 2009, as well as on the board of directors of eResearch Technology, Inc., a public company specializing in contract research clinical services, from July 2008 to April 2012. From March 2009 to June 2010, Mr. DeMane served as a Senior Advisor to Thomas, McNerney & Partners, a healthcare venture firm. Mr. DeMane served as the Chief Operating Officer of Medtronic from August 2007 to April 2008. Prior to his COO role, Mr. DeMane served at Medtronic as Senior Vice President from May 2007 to August 2007, Senior Vice President and President: Europe, Canada, Latin America and Emerging Markets from August 2005 to May 2007, Senior Vice President and President: Spinal, ENT and Navigation from February 2002 to August 2005, and President, Spinal from January 2000 to February 2002. Prior to that, he was President at Interbody Technologies, a division of Medtronic Sofamor Danek, Inc., from June 1998 to December 1999. From April 1996 to June 1998, Mr. DeMane served at Smith & Nephew Pty. Ltd. as Managing Director, Australia and New Zealand, after a series of research and development and general management positions with Smith & Nephew Inc. Mr. DeMane earned a B.S. in Chemistry from St. Lawrence University and an M.S. in Bioengineering from Clemson University.
As the Lead Independent Director of Nevro Corp, the total compensation of Michael DeMane at Nevro Corp is $279,955. There are 13 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.
Michael DeMane is 63, he's been the Lead Independent Director of Nevro Corp since 2019. There are 6 older and 17 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo és & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
Nevro Corp executives and other stock owners filed with the SEC include: